Clinical Trial

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 31, 2025 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is designed to demonstrate PK similarity of the proposed biosimilar test product CT-P52 and the reference product, US-licensed Taltz.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-23.
Status change: Recruiting → Active, Not Recruiting 2025-12-30
Trial Details
NCT Number NCT07200986
Lead Sponsor Celltrion
Conditions Healthy Participants
Enrollment 218 participants
Start Date 2025-09-17
Primary Completion 2026-03-31 (estimated)
Study Completion 2026-03-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-31